Bakgrunn og aktiviteter
Instituttgruppe-tilhørighet: CellebioIogi. Forskergruppetilhørighet: KG Jebsen senter for myelomforskning.
I forskningen min studerer jeg egenskaper hos kreftceller fra pasienter med myelomatose, kreft i beinmargen. Kreftcellene hos pasienter med myelomatose overlever i beinmargen på grunn av stimulerende signaler fra mikromiljøet der. Jeg studerer effekten som slike signaler har på kreftcellene. Målet er å finne angrepspunkter for framtidig behandling av myelomatose. Dersom vi kunne finne medikamenter som avskjærer signaler som er livsviktige for kreftcellene, ville vi potensielt kunne bruke dem til å helbrede pasientene. Vi har blant annet funnet at vekstfaktorer i beinmargen skrur på genene for enzymene PRL-3 og SGK-1 i kreftcellene. Forskningen vår viser at dette er enzymer som har betydning for overlevelse og vekst av cellene og vi arbeider for å kartlegge mer fullstendig den rollen som disse enzymene har.
Vitenskapelig, faglig og kunstnerisk arbeid
Viser et utvalg av aktivitet. Se alle publikasjoner i databasen
Tidsskriftspublikasjoner
- (2013) HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Experimental Hematology. vol. 41 (7).
- (2013) Anti-c-MET Nanobody® – a new potential drug in multiple myeloma treatment. European Journal of Haematology. vol. 91 (5).
- (2012) Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. vol. 26.
- (2012) Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology. vol. 60 (3).
- (2011) Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene. vol. 30 (28).
- (2011) Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: Implications for multiple myeloma. European Journal of Immunology. vol. 41 (2).
- (2011) Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters. European Journal of Haematology. vol. 87 (5).
- (2009) OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. vol. 33 (12).
- (2009) FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). European Journal of Haematology. vol. 83 (5).
- (2008) Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. vol. 111.
- (2007) HGF promotes migration of myeloma cells. Haematologica. vol. 92.
- (2006) Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. vol. 20.
- (2006) HGF Inhibits BMP-Induced Osteoblastogenesis: Implications for the Bone Disease in Multiple Myeloma. Blood. vol. 108.
- (2005) Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica. vol. 90 (4).
- (2004) Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. vol. 23 (17).
- (2004) A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma cells. Clinical Cancer Research. vol. 10.
- (2002) Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. vol. 99.
- (2002) Serum insulin-like growth factor is not increased in patients with multiple myelomna but is still a prognostic factor. Blood. vol. 100.
- (2001) Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scandinavian Journal of Rheumatology. vol. 30 (4).
- (2001) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood. vol. 97 (2).
- (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. vol. 98 (7).
- (2000) Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparing-binding proteins. Blood. vol. 96.
- (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity. Blood. vol. 96 (9).
- (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. vol. 95.
- (1999) Apoptosis, proliferation and NF-k(kappa)B activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. European Journal of Haematology. vol. 63.
- (1999) Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Sedretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. Blood.
- (1999) Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. British Journal of Haematology.
- (1999) Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. Journal of Bone and Mineral Research.
- (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood.
- (1996) Hepatocyte growth factor and its receptor c-MET in multiple myeloma. Blood. vol. 88 (10).
- (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. Journal of Biological Chemistry. vol. 271 (40).
- (1996) The role of the two TNF receptors in proliferation, NF-_KB activation and discrimination between TNF and LT_a signalling in the human myeloma cell line OH-2. Cytokine. vol. 8 (6).